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Abstract
Background: Previous reports suggested a role for iron and hepcidin in atherosclerosis. Here, we evaluated the
causality of these associations from a genetic perspective via (i) a Mendelian randomization (MR) approach, (ii)
study of association of atherosclerosis-related single nucleotide polymorphisms (SNPs) with iron and hepcidin,
and (iii) estimation of genomic correlations between hepcidin, iron and atherosclerosis.
Results: Analyses were performed in a general population sample. Iron parameters (serum iron, serum ferritin, total
iron-binding capacity and transferrin saturation), serum hepcidin and genome-wide SNP data were available for
N = 1,819; non-invasive measurements of atherosclerosis (NIMA), i.e., presence of plaque, intima media thickness and
ankle-brachial index (ABI), for N = 549. For the MR, we used 12 iron-related SNPs that were previously identified in a
genome-wide association meta-analysis on iron status, and assessed associations of individual SNPs and quartiles of
a multi-SNP score with NIMA. Quartile 4 versus quartile 1 of the multi-SNP score showed directionally consistent
associations with the hypothesized direction of effect for all NIMA in women, indicating that increased body iron
status is a risk factor for atherosclerosis in women. We observed no single SNP associations that fit the hypothesized
directions of effect between iron and NIMA, except for rs651007, associated with decreased ferritin concentration
and decreased atherosclerosis risk. Two of six NIMA-related SNPs showed association with the ratio hepcidin/ferritin,
suggesting that an increased hepcidin/ferritin ratio increases atherosclerosis risk. Genomic correlations were close to
zero, except for hepcidin and ferritin with ABI at rest [−0.27 (SE 0.34) and −0.22 (SE 0.35), respectively] and ABI after
exercise [−0.29 (SE 0.34) and −0.30 (0.35), respectively]. The negative sign indicates an increased atherosclerosis risk
with increased hepcidin and ferritin concentrations.
Conclusions: Our results suggest a potential causal role for hepcidin and ferritin in atherosclerosis, and may
indicate that iron status is causally related to atherosclerosis in women.
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Background
In 1981, the ‘iron hypothesis’ was proposed, stating that
iron depletion protects against heart disease [1]. Accord-
ing to this hypothesis, premenopausal women have a
lower risk of heart disease compared to men and post-
menopausal women due to loss of iron with menstruation.
The hypothesis was specified without a mechanism, but it
is proposed that high levels of body iron stores promote
cardiovascular disease (CVD) by catalyzing low-density
lipoprotein (LDL) cholesterol oxidation and thereby
atherosclerosis [2, 3]. Since the proposal of the ‘iron hy-
pothesis’, several epidemiological studies have investigated
the associations between body iron stores and CVD or
(sub)clinical measures of atherosclerosis, but they remain
inconclusive [4–12]. The inconsistent results might be ex-
plained by the fact that it is not the total body iron load,
but the distribution of iron among on the one hand paren-
chymal cells, including the hepatocytes, and on the other
hand the macrophages in the spleen as determined by
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serum hepcidin that drives the association with athero-
sclerosis and CVD risk. Hepcidin regulates systemic iron
homeostasis by controlling the release of iron from i) duo-
denal enterocytes, involved in dietary iron absorption, ii)
macrophages, involved in recycling of iron from senescent
erythrocytes, and iii) hepatocytes, involved in iron storage.
Increased serum hepcidin concentration leads to a de-
creased flow of iron into the bloodstream and an increased
amount of iron trapped inside the iron-exporting cells,
predominantly reticulo-endothelial macrophages [13].
In an extension of the ‘iron hypothesis’ in 2007, hepcidin
has been hypothesized to increase CVD risk by slowing or
preventing the mobilization of iron from macrophages
[14], promoting transformation of these cells into foam
cells and ultimately atherosclerosis [3, 14]. In a recent epi-
demiological study we demonstrated that serum hepcidin
and the ratio of hepcidin to ferritin, i.e., hepcidin expres-
sion relative to body iron stores, are associated with
atherosclerosis in the general population, especially in
postmenopausal women [15]. We did not observe associa-
tions of the iron parameters, i.e., serum ferritin, serum
iron, total-iron binding capacity (TIBC) and transferrin
saturation (TS), with atherosclerosis [15]. However, disen-
tangling the specific causal roles of hepcidin and iron
parameters in atherosclerosis and CVD in observational
population studies is fraught with difficulties due to
potential for residual confounding, reverse causation, and
the existing phenotypic correlations between iron parame-
ters and hepcidin.
In this study, we aimed to investigate the causal roles of
hepcidin, the ratios hepcidin/ferritin and hepcidin/TS, and
the iron parameters in atherosclerosis, as measured by
non-invasive measurements of atherosclerosis (NIMA), by
focusing on their underlying genetics. More specifically, we
1) applied a Mendelian randomization (MR) approach, 2)
evaluated associations of genetic determinants of NIMA
with hepcidin and iron parameters, and 3) estimated the
genomic correlations of hepcidin and the iron parameters
with NIMA based on genome-wide chip data.
In the MR approach, genetic determinants of the risk
factor(s) of interest, in this case iron status and hepcidin,
are used to estimate the causal effect of the risk factor
on a disease outcome, in this case NIMA [16]. As gen-
etic variants are randomly distributed in the population,
this observational design mimics the randomization in a
clinical trial and hence allows for assessment of causa-
lity. This is however only valid if three key assumptions
hold: 1) the genetic variant must be associated with the
exposure, 2) the genetic variant must not directly be
associated with the outcome, and 3) the genetic variant
must not be associated with any confounding factor.
The second step allowed us to evaluate whether
published NIMA-related genetic variants show cross-
trait association with hepcidin and the iron parameters.
This might indicate presence of pleiotropy, where a sin-
gle genetic variant affects multiple traits independently.
It can also indicate a causal relationship between two
correlated traits, where a single genetic variant indirectly
affects a second trait (i.e., NIMA) due to a causal associ-
ation with a first, intermediate trait (i.e., iron and/or
hepcidin).
Third, the estimation of genomic correlations allowed
us to evaluate the extent to which the same genetic vari-
ants, captured via a genome-wide chip, impact on hepci-
din or iron parameters and NIMA. Existence of a genomic
correlation between two traits can indicate pleiotropy or
causality, as for cross-trait associations. A positive gen-
omic correlation indicates that the same genetic variants
influence two traits in the same direction, while a negative
genomic correlation indicates an opposite direction of
effect. The stronger the genomic correlation between two
traits, the larger the amount of shared genetic etiology
between the traits.
The boost in the identification of genetic variants for
complex traits via genome-wide association studies
(GWAS) has facilitated the design of MR studies in recent
years. For the iron parameters, several GWAS have been
published [17–22]. Recently, a large meta-analysis of
GWAS on biochemical markers for iron status was
completed by the Genetics of Iron Status (GIS) Consor-
tium. The study included 23,986 subjects from eleven
population-based studies in the discovery phase and up
to 24,986 subjects in the replication phase [23]. This
meta-analysis led to the identification of 12 single nu-
cleotide polymorphisms (SNPs) statistically significantly
associated with at least one of the iron parameters at a
genome-wide level (Additional file 1: Table S1), which
we used for the current study in the MR analysis
(Additional file 1: Figure S1).
The complex genetic etiology of hepcidin is relatively
unexplored. Traglia et al. published a GWAS on serum
hepcidin in the genetic isolate Val Borbera, in which no
statistically significantly associated loci were found [24].
In addition, studies into the SNPs C282Y (rs1800562) in
the hereditary hemochromatosis gene (HFE) and A736V
(rs855791) in the transmembrane serine protease 6 gene
(TMPRSS6), which have repeatedly been associated with
the iron parameters, only associated with the ratios
hepcidin/ferritin and hepcidin/TS and not with serum
hepcidin [25]. Thus, no genetic determinants of hepcidin
are currently available.
There have also been numerous GWAS into genetic
determinants of NIMA. Sixteen GWAS were combined
in a meta-analysis for common carotid intima media
thickness (IMT) and the presence of carotid plaque
(total N = 42,484), which revealed three (nearest genes
ZHX2, APOC1 and PINX1) and two (nearest genes
PIK3CG and EDNRA) different SNPs that were
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statistically significantly associated with IMT and plaque,
respectively [26]. A meta-analysis of 21 GWAS for
ankle-brachial index (ABI) (total N = 58,409) identified
one genome-wide significant association with nearest
gene CDKN2B [27]. We used these six SNPs to study
cross-trait associations with iron parameters and hepci-
din (Additional file 1: Figure S1 and Table S2).
Here, we studied the roles of hepcidin, the ratios hep-
cidin/ferritin and hepcidin/TS, and the iron parameters
in NIMA by an MR approach, cross-trait associations,
and genomic correlations. We used a subsample of 1819
participants aged 42–76 years from the Nijmegen
Biomedical Study (NBS), a well-phenotyped sample of
the general population.
Methods
Study population
Details of the NBS have been described before [28].
Briefly, the NBS is a population-based survey conducted
by the Radboud university medical center, Nijmegen,
The Netherlands. In 2002, 22,451 age and sex-stratified
randomly selected adult inhabitants of Nijmegen, a city
located in the eastern part of the Netherlands, received
an invitation to fill out a postal questionnaire (QN)
including questions about lifestyle, health status, and
medical history, and to donate a blood sample for DNA
isolation and biochemical studies (NBS-1). A total of
9350 (42 %) persons filled out the QN, of which 6468
(69 %) donated blood samples. In 2005 the second phase
of NBS was started (NBS-2), for which all participants of
the first phase were re-invited to fill out a second ques-
tionnaire. Those who participated in NBS-2 and were
aged 50–70 years at that time were asked to also partici-
pate in the NIMA (non-invasive measurements of
atherosclerosis) substudy performed by the Department
of Internal Medicine. For the NBS-2-NIMA study,
participants had to fill out an additional QN, donate a
fasting blood sample, and undergo anthropometric
measurements and non-invasive measurements of
atherosclerosis. A total of 1491 subjects participated in
NBS-2-NIMA (response 71 %). Approval to conduct the
NBS and NBS-2-NIMA study was obtained from the
Radboud university medical center Institutional Review
Board. All participants gave written informed consent.
Genotype data (Illumina HumanHapCNV370-Duo
BeadChip) were available for those 1980 NBS partici-
pants that were selected to serve as controls in GWAS
[29]. A total of 1819 samples passed quality control
[sample yield ≥96 % (after exclusion of intensity-only
markers (n = 23,573)), Caucasian ancestry ≥90 % (based
on Structure analysis), SNP yield ≥96 %]. Measurements
of hepcidin and the iron parameters (iron, ferritin, TS
and TIBC) were available for all these samples; NIMA
for a subset of 549 participants.
Laboratory methods and clinical measurements
Total serum iron, TIBC, TS and ferritin were measured as
described before.28 Serum hepcidin was measured with an
in-house developed and validated competitive enzyme-
linked immunosorbent assay [30, 31]. We used the follow-
ing NIMA measurements for this study: IMT, presence of
plaque and the ankle-brachial index at rest (ABIR) and
after exercise (ABIEX). The NIMA and total cholesterol
(TC), low-density lipoprotein cholesterol (LDL), high-
density lipoprotein cholesterol (HDL), and triglycerides
(TGC) were measured as described before [15, 32].
Selection and measurement of genetic variants
Genome-wide SNP data were used to estimate genomic
correlations and were available for 1819 NBS participants,
as indicated above. SNP quality control [minor allele fre-
quency (MAF) ≥1 %, and Hardy-Weinberg equilibrium
(HWE) p-value >10−6] resulted in availability of 323,414
SNPs. Density was increased by imputation, which was
performed with 1000genomes phase1 integrated version 3
as a reference sample using IMPUTE v2 software [33].
We used in total 18 SNPs for the MR approach and
cross-trait associations: 12 iron-related SNPs [23]
(Additional file 1: Figure S1 and Table S1) and six
NIMA-related SNPs [26, 27] (Additional file 1: Figure S1
and Table S2). Five of these SNPs were directly mea-
sured (rs1800562, rs855791, rs744653, rs9990333, and
rs6486121) and 13 SNPs were imputed, all of them with
a quality of imputation of >0.99 as measured using the
SNPtest info measure.
Statistical analysis
SNP associations
For the MR approach and cross-trait associations, geno-
type probabilities (P) of the 12 iron-related and 6-NIMA
related SNPs were transformed to dosages, i.e., dosage
per SNP = PAA*0 + PAB*1 + PBB*2; allele B was the effect
allele as presented in Additional file 1: Tables S1 and S2.
We also constructed a multi-SNP score that reflects the
total number of risk alleles. More specifically, we added
the dosages of eight of the 12 iron-related SNPs for
which the hypothesized effects on the risk of athero-
sclerosis according to the ‘iron hypothesis’ were known,
thus excluding rs8177240, rs4921915, rs6486121 and
rs174577 (see Fig. 1). There is no linkage disequilibrium
between these SNPs: six of them are located in different
chromosomes, and rs1800562 and rs1799945 (both
located in gene HFE on chromosome six) show no
correlation [r2 = 0.001 (based on 1000genomes Phase 3
CEU)]. Reference alleles of rs744653, rs1799945,
rs651007, rs411988 and rs855791 were flipped to make
sure that all alleles B were the hypothesized risk-
increasing alleles according to the ‘iron hypothesis’
(Fig. 1). Hepcidin, the hepcidin ratios and ferritin were
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log-transformed to normalize their distributions. For
these log-transformed variables and for the other iron
parameters, standardized residuals adjusted for age,
squared age and time of blood sampling were derived.
This was done separately for men and women to adjust
for gender. Outliers that differed more than four times
the SD from the mean were excluded.
Associations between the single SNPs and multi-SNP
score and traits were studied using logistic (presence of
plaque) and linear (IMT, ABI, hepcidin, hepcidin ratios,
iron parameters) regression models. Resulting odds ratios
(OR) of logistic regression models for the single-SNP
models express the effect of an additional effect allele of
the studied SNP on risk of presence of plaque, i.e., AB vs
AA and BB vs AB. Resulting betas of linear models ex-
press the effect of an additional effect allele of the studied
SNP on measures of IMT, ABI, and on standardized resi-
duals of iron, TS, TIBC, log-hepcidin, log-hepcidin/fer-
ritin, log-hepcidin/TS, and log-ferritin. Associations of the
multi-SNP score with NIMA were assessed after con-
structing quartiles (Q1-4) of the score. ORs and betas for
the multi-SNP score quartiles were generated for Q2, Q3
and Q4 relative to Q1. We also studied the associations
between iron-related SNPs, the multi-SNP score and
NIMA with adjustment for the potential confounding
factors TC, LDL, HDL and TGC, and stratified by gender.
Estimation of genomic correlations and genome-wide
SNP explained variances
We estimated genomic correlations (rG) based on only dir-
ectly measured autosomal SNPs using the software pack-
ages GCTA [34] and Bayz [35]. The use of GCTA to
estimate rG using genome- or chromosome-wide SNPs for
complex traits has been described [36] and applied in other
studies before (e.g., [37]). However, recent results of
Visscher et al. showed that the statistical power to detect
statistically significant rG was limited with a sample size of
N = 1000 [38]. As our sample size for estimation of rG was
smaller than 1000, we also estimated rG with a Bayesian
multivariate model as implemented in the software pack-
age Bayz; this Bayesian analysis handles large sets of traits
in a simultaneous analysis, and therefore we expected Bayz
to produce more precise estimates compared to GCTA,
which is limited to two-trait analysis.
In GCTA, rG are calculated for pairs of traits using the
genetic relationship matrix (GRM) and a bivariate re-
stricted maximum likelihood analysis (GREML) [36]. For
the estimation of the GRM for pairs of individuals we only
retained individuals with a pairwise relationship <0.025 to
remove cryptic relatedness from the data, as recom-
mended by Yang et al.[39]. This resulted in 423 to 431
individuals for the NIMA and 1456 to 1481 individuals for
hepcidin and the iron parameters.
Figure 1 Twelve SNPs identified in meta-GWAS for iron parameters and included in the Mendelian randomization analysis. Betas ± standard error
for serum iron, transferrin, transferrin saturation (TS), and ferritin (log) based on the meta-analyses of genome-wide association studies on iron
status performed by the Genetics of Iron Status Consortium (discovery and replication combined (N = 48,972)). a SNPs that are hypothesized to
increase the risk of atherosclerosis according to the ‘iron hypothesis’; (b) SNPs that are hypothesized to decrease the risk of atherosclerosis
according to the ‘iron hypothesis’; (c) SNPs for which the hypothesized effect on atherosclerosis risk is unknown
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In software package Bayz, Bayesian multivariate models
including up to 8 traits simultaneously were used to esti-
mate rG [35, 40]. The genomic model from Janss et al.
[35] is based on use of an eigenvector decomposition of
the GRM in a random regression model; the GRM used is
the same one as used in GCTA GREML analyses. The
multi-trait implementation makes use of latent variables
to model the covariance [40]. To determine the required
number of latent variables, the Bayesian Deviance Infor-
mation Criterion (DIC) [41] was computed. The Bayesian
model uses uniform priors for variances to express a-
priori ignorance about the model parameters. From the
Bayesian model, the marginal posterior means for rG are
reported. The marginal posterior standard deviation
expresses uncertainty on the estimate, and, with unin-
formative prior distributions, should be similar to the
frequentist SE. For our study, four different multivariate
models were constructed to prevent simultaneous inclu-
sion of highly dependent and correlated variables. Thus,
hepcidin and ferritin were not included in the same model
as the ratio hepcidin/ferritin, as also holds for serum iron
and TIBC with TS, i.e., the ratio of serum iron over TIBC.
Model 1 included hepcidin, ferritin, iron, TIBC, presence
of plaque, IMT, ABIR and ABIEX and was used to deter-
mine rG for all included variables. Model 2 included the
ratio hepcidin/ferritin, iron, TIBC, presence of plaque,
IMT, ABIR and ABIEX, model 3 included the ratio hepci-
din/TS, ferritin, presence of plaque, IMT, ABIR and
ABIEX, and model 4 included hepcidin, ferritin, TS, pres-
ence of plaque, IMT, ABIR and ABIEX; these latter three
models were used to estimate rG for the ratio hepcidin/
ferritin, the ratio hepcidin/TS, and TS, respectively.
Prior to GCTA and Bayz analyses, the following steps
were taken: 1) pairwise LD pruning to remove highly cor-
related SNPs (window size 100, step 5 and r2 0.98) using
the software package PLINK v1.07 [42], resulting in
297,574 SNPs for analysis; 2) log-transformation of the
variables hepcidin, ferritin and the ratios hepcidin/ferritin
and hepcidin/TS to normalize their distributions; 3) trans-
formation of hepcidin, the iron parameters and NIMA to
sex-specific residuals using age, squared age and for hepci-
din and the iron parameters also time of blood sampling
as determinants in regression models; 4) reduction of out-
liers to mean ± 4SD (maximal number of outliers per trait
was six); and 5) standardization of the traits to zero mean
and unit variance.
Results
Characteristics of the subjects included in our study are
presented in Table 1. The percentage of males of the
total study population was 49 % and median age at
inclusion was 63 years. NIMA were available for a subset
of 549 participants (49 % male) with a median age of
59 years.
MR results: associations of iron-related SNPs with IMT,
presence of plaque and ABI
Figure 1 visualizes the effects of the SNPs on the iron
parameters based on the iron meta-GWAS of the GIS
Consortium [23]. The SNPs are classified into their hy-
pothesized effects on the risk of atherosclerosis according
to the ‘iron hypothesis’: SNPs that increase serum iron, TS
and/or ferritin are hypothesized to increase the risk of
atherosclerosis, and vice versa. The hypothesized effect of
rs8177240 is classified as unknown, because the T allele of
this SNP decreases iron and transferrin and increases TS.
The hypothesized effects of rs4921915, rs6486121 and
rs174577 are also classified as unknown, because these
SNPs are only associated with transferrin.
Results of the multi-SNP score and single SNP associ-
ation analyses are presented in Table 2. Effects of the
multi-SNP score on the NIMA were not directionally
consistent with the hypothesized directions of effect. For
the single SNP analyses, only the T allele of rs651007,
associated with decreased ferritin, showed effects that
were consistent with the hypothesized directions of
effects for all NIMA, with nominal significant effects on
IMT [beta −0.021 (95 % CI −0.038; −0.004)] and ABI
after exercise [beta 0.034 (95 % CI 0.004; 0.063)]. SNP
rs9990333 showed a nominally significant association
Table 1 Characteristics of the study population
Variable† Total N Median (P5-P95) or N (%)*
Gender, males 1819 900 (49 %)
Age at inclusion, years 1819 62.9 (42.2–76.0)
Time of blood sampling 1811
Before 12:00 pm 374 (21 %)
Between 12:00 pm and 5:00 pm 1165 (64 %)
After 5:00 pm 272 (15 %)
Serum hepcidin, nmoles/L 1810 7.5 (0.9–22.5)
Serum ferritin, μg/L 1817 120.7 (17.8–421.4)
Hepcidin/ferritin, μmoles/μg 1808 60.3 (20.9–170.3)
Hepcidin/TS, μmoles/L/% 1791 0.25 (0.04–0.96)
Serum iron, μmoles/L 1800 17.0 (9.0–27.0)
TIBC, μmoles/L 1800 58.0 (46.0–75.0)
TS, % 1800 28.8 (14.1–48.1)
IMT, mm 549 0.85 (0.70–1.05)
ABI at rest 549 1.10 (0.96–1.27)
ABI after exercise 542 1.11 (0.76–1.34)
Presence of plaque 549 232 (42 %)
ABI indicates ankle-brachial index, IMT intima media thickness, N number,
P5 fifth percentile, P95 95th percentile, TIBC total iron-binding capacity;
and TS transferrin saturation
*Continuous variables are presented as median (P5-P95). Categorical variables
are presented as N (%)
†Hepcidin, ferritin, hepcidin/ferritin, hepcidin/TS, iron, TIBC, TS and time of
blood sampling were measured in 2002 and presence of plaque, IMT, and ABI
at rest and after exercise were measured between 2005 and 2008
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Table 2 Association of the iron-related SNPs with non-invasive measurements of atherosclerosis
Presence of plaque IMT ABI at rest ABI after exercise
SNP – Tested allele CHR:BP (Build 37) Freq H* OR 95 % CI H* Beta 95 % CI H* Beta 95 % CI H* Beta 95 % CI
Multi-SNP score
Q1 Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Q2 >1 1.06 0.66; 1.71 + −0.024 −0.051; 0.002 - 0.003 −0.022; 0.028 - −0.024 −0.051; 0.002
Q3 >1 0.82 0.51; 1.34 + −0.007 −0.034; 0.020 - 0.005 −0.021; 0.030 - −0.007 −0.034; 0.020
Q4 >1 1.13 0.70; 1.82 + 0.009 −0.018; 0.036 - 0.003 −0.022; 0.028 - 0.009 −0.018; 0.036
rs744653 – T 2:190,378,750 0.86 <1 1.10 0.78; 1.55 - −0.006 −0.025; 0.014 + −0.013 −0.031; 0.005 + −0.019 −0.052; 0.014
rs8177240 – T† 3:133,477,701 0.66 ? 1.13 0.87; 1.46 ? −0.010 −0.025; 0.004 ? 0.014 0.000; 0.027 ? 0.030 0.005; 0.055
rs9990333 – T 3:195,827,205 0.47 >1 1.32 1.03; 1.68 + 0.012 −0.002; 0.025 - 0.006 −0.006; 0.019 - 0.016 −0.007; 0.040
rs1800562 – A 6: 26,093,141 0.06 >1 1.03 0.62; 1.69 + −0.017 −0.045; 0.011 - −0.006 −0.032; 0.020 - −0.005 −0.054; 0.043
rs1799945 – C 6: 26,091,179 0.84 <1 1.19 0.86; 1.64 - 0.011 −0.007; 0.029 + 0.003 −0.014; 0.019 + −0.006 −0.037; 0.024
rs7385804 – A 7: 100,235,970 0.64 >1 0.92 0.72; 1.18 + −0.006 −0.020; 0.008 - 0.000 −0.013; 0.013 - 0.018 −0.006; 0.042
rs4921915 – A‡ 8: 18,272,466 0.78 ? 1.42 1.04; 1.92 ? −0.006 −0.023; 0.010 ? 0.002 −0.014; 0.017 ? 0.005 −0.023; 0.034
rs651007 – T 9: 136,153,875 0.20 <1 0.84 0.62; 1.15 - −0.021 −0.038; 0.004 + 0.003 −0.013; 0.019 + 0.034 0.004; 0.063
rs6486121 – T‡ 11: 13,355,770 0.64 ? 0.94 0.73; 1.20 ? 0.012 −0.002; 0.026 ? −0.004 −0.017; 0.009 ? −0.007 −0.031; 0.018
rs174577 – A‡ 11: 61,604,814 0.32 ? 1.10 0.85; 1.42 ? 0.001 −0.013; 0.015 ? 0.004 −0.009; 0.017 ? 0.015 −0.009; 0.040
rs411988 – A 17: 56,709,034 0.58 <1 0.92 0.73;1.17 - −0.001 −0.015; 0.012 + 0.004 −0.008; 0.017 + −0.010 −0.033; 0.013
rs855791 – A 22: 37,462,936 0.46 <1 1.20 0.94; 1.54 - −0.010 −0.023; 0.004 + 0.005 −0.008; 0.018 + 0.010 −0.013; 0.034
Associations were tested using logistic (presence of plaque) and linear regression (IMT and ABI at rest and after exercise). Resulting odds ratios (OR) of logistic models for the multi-SNP score express the change in
odds for presence of plaque relative to Q1. Resulting betas of linear models for the multi-SNP score express the change in IMT or ABI using Q1 as a reference, thus Q2 vs Q1, Q3 vs Q1 and Q4 vs Q1. Resulting ORs of
logistic regression models for the single SNP analyses express the effect of each extra tested allele on odds for presence of plaque. Resulting betas of linear models for the single SNP analyses express the effect of each
extra tested allele on IMT or ABI. Tested alleles are the same as in the original publication [23]. Nominally significant associations are indicated in bold
ABI indicates ankle-brachial index, CHR:BP chromosome:base-pair position, CI confidence interval, Freq frequency of tested allele, H hypothesized effect, IMT intima media thickness, OR odds ratio, Ref reference,
Q quartile, SNP single nucleotide polymorphism
*Hypothesized effect on the NIMA according to the ‘iron hypothesis’ (see Fig. 1). Presence of plaque, a higher IMT and a lower ABI indicate presence of atherosclerosis
†This SNP decreases iron and transferrin and increases TS, so the hypothesized effect on atherosclerosis is unknown
‡These SNPs only show association with transferrin, so the hypothesized effect on atherosclerosis is unknown
G
alesloot
et
al.BM
C
G
enetics
 (2015) 16:79 
Page
6
of
12
with presence of plaque that was directionally consistent
[OR 1.32 (95 % CI 1.03; 1.68)], but this SNP showed in-
consistent, nonsignificant effects on other NIMA. Two
other nominally significant effects were found for
rs8177240 and rs4921915, but their hypothesized direc-
tions of effect were unknown. Adjustment of the single
SNP and multi-SNP score associations with NIMA for
TC, LDL, HDL and TGC revealed similar results
(Additional file 1: Table S3).
Stratification by gender revealed no directionally con-
sistent associations of the multi-SNP score with all NIMA
in men. However, in women all directions of effect of Q4
compared to Q1 of the score were directionally consistent
with the hypothesized direction of effect (Additional file 1:
Table S4). This included a nominally significant associ-
ation for Q4 vs Q1 of the score with IMT [beta 0.033
(95 % CI 0.000;0.067)]. For the single SNP analyses, effects
of rs651007 were consistent with the hypothesized direc-
tions of effects for all NIMA in men and for all NIMA ex-
cept for ABI at rest in women (Additional file 1: Table S4).
The effect of rs651007 on IMT was stronger in women,
whereas the effect of rs651007 on presence of plaque and
ABI after exercise was stronger in men. In addition to
rs651007, rs855791 showed consistent associations with
all NIMA in men, whereas rs1799945 and rs7385804
showed consistent associations with all NIMA in women.
Effect estimates of the single SNP associations were not
systematically higher or lower in men or women. Asso-
ciations of the gender-specific results remained similar
after adjustment for TC, LDL, HDL, and TGC (Additional
file 1: Table S5).
Association of NIMA-related SNPs with the iron
parameters and hepcidin
Associations of top SNPs for IMT, plaque and ABI with
hepcidin, the ratios hepcidin/ferritin and hepcidin/TS,
and the iron parameters are shown in Additional file 1:
Table S6. Three nominally significant associations were
observed. The IMT-associated SNP rs11781551 showed
association with the ratio hepcidin/ferritin, in addition
to the ABI-associated SNP rs10757269, and observed
directions of effect were consistent with hypothesized
directions for both SNPs.
Genomic correlations
Tables 3 and 4 show the genomic correlations of hepci-
din, the ratios hepcidin/ferritin and hepcidin/TS, and
the iron parameters with NIMA as obtained by GCTA
(Table 3) and Bayz (Table 4). Point estimates of genomic
correlations resulting from the two methods were mostly
dissimilar. A substantial part of the estimates by GCTA
resulted in values of 0, −1 or 1, indicating convergence
of the models to extremes, as expected due to our
relatively small sample size.
Bayz estimates of genomic correlations with NIMA
were very weak (i.e., close to 0), except for the genomic
correlation of hepcidin and ferritin with ABI at rest
[−0.27 (SE 0.34) and −0.22 (SE 0.35), respectively] and
ABI after exercise [−0.29 (SE 0.34) and −0.30 (0.35),
respectively].
Evidence for and against a role of hepcidin and the
iron parameters in atherosclerosis based on the results
of the current study is summarized in Table 5.
Discussion
In this study, we investigated relationships of iron parame-
ters and hepcidin with NIMA in a sample of the general
population by performing an MR approach, assessing as-
sociations of NIMA-related SNPs with iron parameters
and hepcidin, and studying genomic correlations of iron
parameters, hepcidin, and hepcidin ratios with NIMA.
Overall, the results suggest a potential role for ferritin and
hepcidin in atherosclerosis, and indicate a potential causal
role of iron status on NIMA in women (Table 5).
Table 3 Genomic correlations (SE) estimated with GCTA
Presence
of plaque
IMT ABI at rest ABI after
exercise
Hepcidin 0.18 (1.48) 0.11 (1.49) 0.01 (1.29) 0.02 (1.40)
Ferritin 0.15 (1.49) −1.00 (4.74) 1.00 (38.1) 0.01 (1.45)
Hepcidin/ferritin −1.00 (4.35) 0.09 (4.35) −1.00 (>4E5) 0.25 (2.39)
Hepcidin/TS −1.00 (15.38) −1.00 (4.87) 0.02 (1.37) 0.01 (1.24)
Iron 0.05 (1.53) 1.00 (4.18) 0.08 (1.05) −1.00 (38.1)
TIBC 1.00 (17.3) 0.04 (1.16) 1.00 (55.5) −1.00 (113.7)
TS 0.06 (1.36) 1.00 (147.7) 0.06 (0.96) 1.00 (>1E5)
ABI indicates ankle-brachial index, IMT intima media thickness, SE standard
error, TIBC total iron-binding capacity; and TS transferrin saturation
Table 4 Genomic correlations (SE) estimated with Bayz
Presence
of plaque
IMT ABI at rest ABI after
exercise
Hepcidin* 0.01 (0.27) −0.01 (0.31) −0.27 (0.34) −0.29 (0.34)
Ferritin* −0.03 (0.28) 0.01 (0.32) −0.22 (0.35) −0.30 (0.35)
Hepcidin/ferritin† 0.06 (0.21) −0.02 (0.24) −0.10 (0.27) −0.01 (0.28)
Hepcidin/TS‡ 0.12 (0.19) 0.10 (0.21) −0.07 (0.27) 0.03 (0.29)
Iron* −0.04 (0.20) 0.06 (0.21) 0.04 (0.25) 0.09 (0.26)
TIBC* −0.01 (0.14) 0.04 (0.15) −0.08 (0.16) −0.07 (0.17)
TS§ −0.01 (0.19) 0.00 (0.19) 0.05 (0.21) 0.04 (0.22)
ABI indicates ankle-brachial index, IMT intima media thickness, SE standard
error, TIBC total iron-binding capacity, and TS transferrin saturation
*Correlations in these rows come from an 8-trait analysis including hepcidin,
ferritin, iron, TIBC, presence of plaque, IMT, ABI at rest and ABI after exercise
†Correlations in this row come from a 7-trait analysis including the ratio
hepcidin/ferritin, iron, TIBC, presence of plaque, IMT, ABI at rest and ABI
after exercise
‡Correlations in this row come from a 6-trait analysis including the ratio
hepcidin/TS, ferritin, presence of plaque, IMT, ABI at rest and ABI after exercise
§Correlations in this row come from a 7-trait analysis including hepcidin,
ferritin, TS, presence of plaque, IMT, ABI at rest and ABI after exercise
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The results from the current study partly confirm the
results from our previous observational study [15]. In
this previous study we did not find associations of the
four iron parameters with NIMA, except for serum iron
and TS with IMT in women, although the trend over
quartiles of serum iron and TS was not completely con-
sistent. In the current study we found an indication for a
potential causal effect of iron status as a whole on NIMA
in women only, with a nominally significant association
for Q4 vs Q1 of the multi-SNP score and IMT, which
might corroborate the original ‘iron hypothesis’. In
addition, the findings of our current study provide weak
evidence that hepcidin, ferritin and the ratio hepcidin/fer-
ritin are causally related to atherosclerosis, which confirms
the extended ‘iron hypothesis’ and results of our observa-
tional study that indicated that the iron distribution, as
determined by serum hepcidin and the ratio hepcidin/fer-
ritin, plays a role in the development of atherosclerosis.
We used three different approaches to assess causality
of the associations between hepcidin, iron and athero-
sclerosis. First, the multi-SNP score that we constructed
based on iron-related SNPs showed directionally
consistent associations with all NIMA in women, but
not in men. This score reflects iron status as a whole, as
the eight SNPs that were combined in this score asso-
ciate with all four iron parameters. It indicates that an
increased body iron status increases the risk of athero-
sclerosis in women, thus corroborating with the original
‘iron hypothesis’. From the single SNP analyses, however,
we did not obtain evidence for a causal role of the iron
parameters on NIMA. For all but one of the 12 SNPs,
directions of effect were inconsistent over the four
NIMA and/or inconsistent with the hypothesized direc-
tion of effect according to the ‘iron hypothesis’. The ex-
ception was rs651007, which is uniquely associated with
a decrease in ferritin concentration and which showed a
decreased risk of atherosclerosis. However, rs411988,
which is also uniquely associated with ferritin with a
similar effect estimate as for rs651007, showed far
weaker or even no associations with the NIMA. One
would expect similar results for these two SNPs [43],
thus the MR approach provides contradicting evidence
for a causal role of ferritin in atherosclerosis. The fact
that results of our multi-SNP score analyses indicated a
Table 5 Summary of evidence for and against a role of hepcidin and the iron parameters in atherosclerosis resulting from this study
Trait Evidence for causal role Evidence against causal role
Hepcidin Weak genomic correlations with ABI
at rest and ABI after exercise
- No nominally significant associations with all NIMA-related SNPs
- Genomic correlations with presence of plaque and IMT ~0
Ferritin - Directionally consistent associations of
the multi-SNP score with NIMA in women
- No directionally consistent associations of the multi-SNP score with NIMA in men
- Directionally consistent associations
of rs651007 with NIMA
-No directionally consistent associations of other variants than rs651007
(notably rs411988) with NIMA
- Weak genomic correlations with ABI
at rest and ABI after exercise
- No nominally significant associations with all NIMA-related SNPs
- Genomic correlations with presence of plaque and IMT ~0
Hepcidin/ferritin Nominally significant associations
with two NIMA-related SNPs
- No nominally significant associations with four NIMA-related SNPs
- Genomic correlations with all NIMA ~0
Hepcidin/TS - No nominally significant associations with all NIMA-related SNPs
- Genomic correlations with all NIMA ~0
Iron - Directionally consistent associations of the
multi-SNP score with NIMA in women
- No directionally consistent associations of the multi-SNP score with NIMA in men
- No directionally consistent associations of iron-related SNPs with NIMA
- No nominally significant associations with all NIMA-related SNPs
- Genomic correlations with all NIMA ~0
TIBC - Directionally consistent associations of the
multi-SNP score with NIMA in women
- No directionally consistent associations of the multi-SNP score with NIMA in men
- No directionally consistent associations of iron-related SNPs with NIMA
- No nominally significant associations with all NIMA-related SNPs
- Genomic correlations with all NIMA ~0
TS - Directionally consistent associations of the
multi-SNP score with NIMA in women
- No directionally consistent associations of the multi-SNP score with NIMA in men
- No directionally consistent associations of iron-related SNPs with NIMA
- No nominally significant associations with all NIMA-related SNPs
- Genomic correlations with all NIMA ~0
ABI indicates ankle-brachial index, IMT intima media thickness, NIMA non-invasive measurement of atherosclerosis, SNP single nucleotide polymorphism,
TIBC total iron-binding capacity, and TS transferrin saturation
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causal effect of iron status on atherosclerosis in women,
whereas results of the single SNP analyses did not,
might be due to a difference in power. The combination
of multiple variants into a score can increase power, as
the score will explain a larger proportion of variation in
the iron parameters than the single variants [44]. The
causal effects of hepcidin on atherosclerosis could not
be studied by an MR approach, as there have been no
SNPs identified yet that have been validated for associ-
ation with hepcidin.
Secondly, the reverse approach of studying associations
of NIMA-associated top SNPs with the iron parameters,
as was previously done for coronary artery disease and
IMT [45], failed to provide evidence for a role of ferritin,
iron, TIBC and TS in atherosclerosis. We did not observe
any significant and consistent associations, thus indicating
no intermediate or pleiotropic effects of these SNPs on all
four iron parameters. Furthermore, the nearest genes for
NIMA-associated top SNPs are currently not known to be
involved in iron metabolism. The NIMA-related SNPs did
also not associate with hepcidin, but two of them did show
nominally significant associations with the ratio hepcidin/
ferritin, with consistency in observed and hypothesized
directions of effect. This indicates that the ratio hepcidin/
ferritin and thus the body iron distribution might be
involved in atherosclerosis. Notably, two previous studies
reported the SNPs rs12091564 and rs10218795 in the
hemochromatosis type 2 gene (HFE2; also known as
hemojuvelin [HJV]) to be associated with coronary artery
disease (CAD) based on a two-marker association test and
haplotype analysis [46, 47]. Defects in HFE2 lead to a form
of juvenile hemochromatosis, which is characterized by a
severe iron overload (high serum ferritin, high TS) mainly
in the parenchyma due to a low hepcidin/ferritin ratio, oc-
curring typically before the age of 30. This finding is thus
in contrast to the extended ‘iron hypothesis’ that it is the
iron loading in the reticulo-endothelial system as deter-
mined by hepcidin that promotes the development of
atherosclerosis. It also contradicts the general clinical im-
pression that hereditary hemochromatosis associated with
parenchymal iron overload is not associated with in-
creased atherosclerosis [48]. As the HFE2 gene is also
expressed in heart and skeletal muscle, it could also be
that the SNPs in HFE2 do not necessarily associate with
CAD via iron.
Third, genomic correlations of the iron parameters
with the NIMA were close to zero, thus indicating that
there is no overlap in genetic etiology of the traits. Ex-
ception was the modest negative genomic correlation of
ferritin with ABI at rest and ABI after exercise, indicat-
ing that genetic variants that increase ferritin cause a de-
crease in ABI. However, these genomic correlations were
far from statistically significant and ferritin did not show
genomic correlations with other NIMA. We observed a
negative genomic correlation of hepcidin with ABI at
rest and after exercise, although in our previous observa-
tional study we did not find hepcidin to be associated
with ABI at rest and ABI after exercise, but only the
ratio hepcidin/ferritin [15]. However, the genomic cor-
relation of the ratio hepcidin/ferritin with ABI at rest
and after exercise in the current study was close to zero.
Furthermore, we found a significant association of
hepcidin and hepcidin/ferritin with presence of plaque
in our previous observational study, but genomic corre-
lations between these variables in the current study were
very weak.
Our results on the potential role of hepcidin and the
ratio hepcidin/ferritin in atherosclerosis are in agree-
ment with findings on the role of hepcidin in patient
populations and in vitro and mice studies, as discussed
in our previous study [15]. They are in contrast to a
mouse study recently published by Kautz et al. [49], which
indicated that increased macrophage iron as a result of a
loss-of-function ferroportin mutation, mimicking the
effect of increased hepcidin concentration, does not pro-
mote atherosclerosis. However, studies in a similar mouse
model showed that pharmacological suppression of hepci-
din does reduce atherosclerosis [50], and that hepcidin
overexpression did change plaque composition although
not plaque size [51]. Kautz et al. explain their discrepant
finding by suggesting that the effect of macrophage iron
on atherosclerosis could be so small that contradictory
conclusions might be reached due to differences in study
design [49]. They also propose that hepcidin might be in-
creased locally in macrophages and adipocytes in the
plaque environment and may promote local macrophage
iron accumulation [49].
There are some aspects that hampered our study. First
of all, the size of our study population was limited. Stud-
ies that investigated the power of MR analyses indicate
that several thousands of individuals are actually needed
to allow for powerful MR studies [52, 53]. Our limited
sample size resulted in imprecise estimates of genomic
correlations, suboptimal power of our MR analysis and
low power to identify SNP associations with statistical
significance. Consequently, our results are of an explora-
tive character in which we focused on directions of ob-
served effect estimates and their consistency with the
hypothesized direction of effect. In addition, the limited
sample size decreased the power of our gender-stratified
MR analyses, which we performed based on our previ-
ous gender-specific findings [15]. Secondly, our estima-
tion of genomic correlations provided us with indirect
evidence of a potential causal relation between these
traits; strong genomic correlations can be the result of
pleiotropy and are not evidence for causality per se.
Also, weak genomic correlations do not exclude causal
relationships, as causality can also be the result of
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(shared) environmental factors only. In addition, the
genomic correlations that we reported were based on
measured autosomal and common SNPs only. Further-
more, the multi-SNP score that we made reflects iron
status as a whole and does not enable to conclude which
one of the iron parameters is actually causally related to
atherosclerosis risk. Finally, causal inference based on the
MR approach is only valid if three crucial assumptions
hold, as described in the Introduction. It was limited by
the fact that most of the 12 SNPs that we included in our
MR approach influence more than one of the iron param-
eters. Furthermore, the SNPs rs1800562 in HFE and
rs855791 in TMPRSS6 also showed association with the
ratios hepcidin/ferritin and hepcidin/TS [24, 25], and with
red blood cell traits (e.g., [54, 55]). In addition, four of the
loci that were found in the iron status meta-GWAS have
been reported as lipid loci by the Global Lipids Genetics
Consortium [56], i.e., HFE, NAT2, ABO and FADS2. How-
ever, performing the MR analyses using TC, LDL, HDL
and TGC as covariates did not change our conclusions.
Still, the overlap in iron and lipid loci is substantial and is
therefore unlikely to be based on chance only. It might in-
dicate causal relationships between iron status and lipid
levels and therefore also atherosclerosis, which was con-
firmed by the associations of the multi-SNP score with
NIMA in women in our current study.
Conclusions
This study is the first to evaluate the ‘iron hypothesis’
from a genetic point of view. Our results suggest that an
increased iron status plays a causal role in the develop-
ment of atherosclerosis in women. Our results are also
suggestive for a potential causal role of ferritin and
hepcidin in atherosclerosis. We warrant future studies to
exploit any new genetic variants that are found to be
associated with serum hepcidin in an MR approach. In
addition, we emphasize follow-up of the current study in
a larger series including multiple study populations to
allow for adequately powered MR studies.
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